Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross‐resistance to a wide range of DNA‐damaging drugs
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Although DNA‐damaging agents are among the most effective anticancer drugs in clinical use, their overall effectiveness is limited by the development of cross‐resistance to these drugs. Given that histone deacetylase (HDAC) inhibitors increase the acetylation of core histones, resulting in an open chromatin configuration that is more accessible to DNA‐targeting agents, we examined whether HDAC inhibitors might enhance the cytotoxicity of DNA‐damaging drugs in six human ovarian tumor cell lines that exhibit different cisplatin sensitivities. Low concentrations of HDAC inhibitors, which alone exhibited little cytotoxicity, markedly enhanced the induction of apoptotic cell death not only by cisplatin but also by a wide variety of DNA‐targeting anticancer drugs in these tumor cell lines, irrespective of their sensitivities to the respective drugs. In contrast, HDAC inhibitors did not increase the cytotoxicity of metabolic antagonists or microtubule‐targeting agents. HDAC inhibitors potentiated both the phosphorylation of histone H2AX on serine‐139 (a marker of DNA double‐strand breaks) as well as the accumulation of reactive oxygen species induced by DNA‐damaging agents in tumor cells. The enhanced generation of reactive oxygen species appeared to be responsible for the enhanced apoptotic cell death induced by the combination of these drugs. These results indicate that the combination of an HDAC inhibitor with a wide variety of DNA‐damaging agents is a promising chemotherapeutic strategy for the eradication of tumor cells, regardless of whether the cells are sensitive or resistant to the DNA‐damaging anticancer drugs. (Cancer Sci 2008; 99: 376–384)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139
Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S., & Bonner, W. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5858 · Cited by 5,438
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Lund, A. H., & van Lohuizen, M. (2004) · Genes & Development · doi:10.1101/gad.1232504 · Cited by 489
Cited by
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
What is triple-negative breast cancer?
Irvin, W. J., & Carey, L. A. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.034 · Cited by 350
Lin, C.-H., Chen, C.-H., Lin, Z.-C., & Fang, J.-Y. (2017) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2017.02.001 · Cited by 298
Griffith, D., Morgan, M. P., & Marmion, C. J. (2009) · Chemical Communications · doi:10.1039/b916715c · Cited by 109
Parker, J. P., Nimir, H., Griffith, D. M., Duff, B., Chubb, A. J., Brennan, M. P., Morgan, M. P., Egan, D. A., & Marmion, C. J. (2013) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2013.03.011 · Cited by 32
Metadata
- Authors
- Ozaki, K., Kishikawa, F., Tanaka, M., Sakamoto, T., Tanimura, S., & Kohno, M.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2008-01-15
- Volume
- 99
- Issue
- 2
- Pages
- 376-384
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W1978835020
- Cited by
- 85
- References
- 5
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross‐resistance to a wide range of DNA‐damaging drugs. https://app.cochat.ai/papers/10.1111/j.1349-7006.2007.00669.x
- The paper
- Ozaki, K., Kishikawa, F., Tanaka, M., Sakamoto, T., Tanimura, S., & Kohno, M. (2008). Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross‐resistance to a wide range of DNA‐damaging drugs. Cancer Science. https://doi.org/10.1111/j.1349-7006.2007.00669.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.